慢性淋巴细胞白血病肿瘤性B细胞上2型补体受体（CR2）表达降低。
Decreased expression of complement receptor type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia.
作者信息
Tooze J A, Bevan D H
机构信息
Department of Cellular and Molecular Sciences, St George's Hospital Medical School, London, England.
出版信息
Clin Exp Immunol. 1991 Mar;83(3):423-9. doi: 10.1111/j.1365-2249.1991.tb05655.x.
Abstract
Neoplastic cells from 49 patients with B cell chronic lymphocytic leukaemia (B-CLL) were studied and compared with normal peripheral and tonsillar B cells using CD21 monoclonal antibodies. Membrane expression of CR2 was quantified by calibrated flow cytometry and by binding analysis with radiolabelled antibody. Both assays indicate that B-CLL cells express only 30% of the CR2 found on normal B cells. These findings are further evidence of the aberrant phenotype of B-CLL cells.
摘要
对49例B细胞慢性淋巴细胞白血病（B-CLL）患者的肿瘤细胞进行了研究，并使用CD21单克隆抗体与正常外周血和扁桃体B细胞进行比较。通过校准流式细胞术和用放射性标记抗体的结合分析对CR2的膜表达进行定量。两种检测均表明，B-CLL细胞仅表达正常B细胞上发现的CR2的30%。这些发现进一步证明了B-CLL细胞异常的表型。
相似文献
1
Decreased expression of complement receptor type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia.慢性淋巴细胞白血病肿瘤性B细胞上2型补体受体（CR2）表达降低。
Clin Exp Immunol. 1991 Mar;83(3):423-9. doi: 10.1111/j.1365-2249.1991.tb05655.x.
2
3
Phenotypic analysis of receptor-ligand pairs on B-cells in B-chronic lymphocytic leukemia.B 细胞慢性淋巴细胞白血病中 B 细胞上受体 - 配体对的表型分析
Leuk Lymphoma. 1997 Apr;25(3-4):301-11. doi: 10.3109/10428199709114169.
4
Complement activation by malignant B cells from patients with chronic lymphocytic leukaemia (CLL).慢性淋巴细胞白血病（CLL）患者恶性B细胞的补体激活。
Clin Exp Immunol. 1995 Dec;102(3):575-81. doi: 10.1111/j.1365-2249.1995.tb03855.x.
5
Soluble forms of CD21 and CD23 antigens in the serum in B cell chronic lymphocytic leukaemia.B细胞慢性淋巴细胞白血病患者血清中CD21和CD23抗原的可溶性形式
Immunol Lett. 1989 Jan 31;20(2):103-9. doi: 10.1016/0165-2478(89)90093-x.
6
Immunophenotype analysis of B-CLL lymphoma and immunocytoma.B细胞慢性淋巴细胞白血病淋巴瘤和免疫细胞瘤的免疫表型分析。
APMIS. 1989 Nov;97(11):1025-32. doi: 10.1111/j.1699-0463.1989.tb00513.x.
7
A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.CD21低表型，且无针对补体蛋白自身抗体的证据，这与慢性淋巴细胞白血病的不良预后一致。
Oncotarget. 2015 Oct 20;6(32):32669-80. doi: 10.18632/oncotarget.5404.
8
Phenotypic heterogeneity of B cell chronic lymphocytic leukaemia.B 细胞慢性淋巴细胞白血病的表型异质性
Immunol Lett. 1988 Dec;19(4):269-71. doi: 10.1016/0165-2478(88)90153-8.
9
IL-13 has only a subset of IL-4-like activities on B chronic lymphocytic leukaemia cells.白细胞介素-13对B慢性淋巴细胞白血病细胞仅具有一部分类似于白细胞介素-4的活性。
Immunology. 1994 Nov;83(3):397-403.
10
Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19.补体系统与免疫系统的交叉：含2型补体受体和CD19的B淋巴细胞信号转导复合体
J Exp Med. 1991 Jan 1;173(1):55-64. doi: 10.1084/jem.173.1.55.
引用本文的文献
1
A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.CD21低表型，且无针对补体蛋白自身抗体的证据，这与慢性淋巴细胞白血病的不良预后一致。
Oncotarget. 2015 Oct 20;6(32):32669-80. doi: 10.18632/oncotarget.5404.
2
Contribution of follicular dendritic cells to persistent HIV viremia.滤泡树突状细胞对持续性 HIV 病毒血症的贡献。
J Virol. 2013 Jul;87(14):7893-901. doi: 10.1128/JVI.00556-13. Epub 2013 May 8.
3
B-cell activity in children with malaria.儿童疟疾中的 B 细胞活性。
Malar J. 2012 Mar 9;11:66. doi: 10.1186/1475-2875-11-66.
4
Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis.高效抗逆转录病毒治疗期间HIV-1从滤泡树突状细胞的解离：数学分析
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14681-6. doi: 10.1073/pnas.96.26.14681.
5
Complement activation by malignant B cells from patients with chronic lymphocytic leukaemia (CLL).慢性淋巴细胞白血病（CLL）患者恶性B细胞的补体激活。
Clin Exp Immunol. 1995 Dec;102(3):575-81. doi: 10.1111/j.1365-2249.1995.tb03855.x.
本文引用的文献
1
Paraformaldehyde fixation of hematopoietic cells for quantitative flow cytometry (FACS) analysis.用于定量流式细胞术（FACS）分析的造血细胞多聚甲醛固定。
J Immunol Methods. 1981;47(1):25-30. doi: 10.1016/0022-1759(81)90253-2.
2
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.一项基于多变量生存分析得出的慢性淋巴细胞白血病新预后分类。
Cancer. 1981 Jul 1;48(1):198-206. doi: 10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v.
3
4
Expression of cell surface markers after human B lymphocyte activation.人B淋巴细胞活化后细胞表面标志物的表达。
Proc Natl Acad Sci U S A. 1981 Jun;78(6):3848-52. doi: 10.1073/pnas.78.6.3848.
5
6
Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1).鉴定一种对膜补体受体1（CR1）具有特异性的抗单核细胞单克隆抗体。
Eur J Immunol. 1984 Mar;14(3):236-43. doi: 10.1002/eji.1830140307.
7
Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production by human B cells.爱泼斯坦-巴尔病毒诱导人B细胞产生免疫球蛋白的有限稀释分析。
J Exp Med. 1983 Jan 1;157(1):1-14. doi: 10.1084/jem.157.1.1.
8
Monoclonal antibodies to Epstein-Barr virus-induced, transformation-associated cell surface antigens: binding patterns and effect upon virus-specific T-cell cytotoxicity.针对爱泼斯坦-巴尔病毒诱导的、转化相关细胞表面抗原的单克隆抗体：结合模式及其对病毒特异性T细胞细胞毒性的影响。
Int J Cancer. 1982 Apr 15;29(4):373-81. doi: 10.1002/ijc.2910290403.
9
10
Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes.鉴定一种145,000道尔顿的膜蛋白为人B淋巴细胞的C3d受体（CR2）。
Proc Natl Acad Sci U S A. 1984 Feb;81(3):881-5. doi: 10.1073/pnas.81.3.881.
Zotero 插件